Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
JERSEY, Channel Islands, May 31, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7, 2017 at 3:00 p.m. Eastern Time at the Grand Hyatt New York.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
